Celgene Stock Total Debt
Celgene fundamentals help investors to digest information that contributes to Celgene's financial success or failures. It also enables traders to predict the movement of Celgene Stock. The fundamental analysis module provides a way to measure Celgene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Celgene stock.
Celgene |
Celgene Company Total Debt Analysis
Celgene's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Celgene Total Debt | 20.1 B |
Most of Celgene's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Celgene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, Celgene has a Total Debt of 20.1 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The total debt for all United States stocks is significantly lower than that of the firm.
Celgene Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Celgene's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Celgene could also be used in its relative valuation, which is a method of valuing Celgene by comparing valuation metrics of similar companies.Celgene is currently under evaluation in total debt category among its peers.
Celgene Fundamentals
Return On Equity | 1.0E-4 | |||
Return On Asset | 0.14 | |||
Profit Margin | 0.30 % | |||
Operating Margin | 51.47 % | |||
Current Valuation | 85.34 B | |||
Shares Outstanding | 708.74 M | |||
Shares Owned By Insiders | 0.22 % | |||
Shares Owned By Institutions | 77.62 % | |||
Number Of Shares Shorted | 12.95 M | |||
Price To Earning | 13.31 X | |||
Price To Book | 7.45 X | |||
Price To Sales | 4.54 X | |||
Revenue | 16.35 B | |||
Gross Profit | 14.06 B | |||
EBITDA | 8.42 B | |||
Net Income | 5.27 B | |||
Cash And Equivalents | 9.32 B | |||
Cash Per Share | 13.15 X | |||
Total Debt | 20.1 B | |||
Debt To Equity | 199.90 % | |||
Current Ratio | 3.44 X | |||
Book Value Per Share | 9.22 X | |||
Cash Flow From Operations | 6.35 B | |||
Short Ratio | 3.45 X | |||
Earnings Per Share | 7.32 X | |||
Price To Earnings To Growth | 0.67 X | |||
Number Of Employees | 8.85 K | |||
Beta | 1.41 | |||
Market Capitalization | 77.04 B | |||
Total Asset | 1.11 B | |||
Retained Earnings | 21.79 B | |||
Working Capital | 708.47 M | |||
Current Asset | 849.88 M | |||
Current Liabilities | 141.41 M | |||
Z Score | 69.79 |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Celgene Stock
If you are still planning to invest in Celgene check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Celgene's history and understand the potential risks before investing.
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |